Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - alprazolam, quantity: 1 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; maize starch; docusate sodium; colloidal anhydrous silica; magnesium stearate; sodium benzoate; lactose monohydrate; indigo carmine aluminium lake; microcrystalline cellulose; povidone - for short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. alprazolam is not recommended as primary therapy in patients with depression. for the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. indications as at 17 december 2001 : anxiety. short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. panic disorder. the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. the diagnostic criteria for panic disorder in dsm-iii-r are as follows: the panic attacks (discrete periods of intense fear or discomfort), at least initially, are unexpected. later in the course of this disturbance, certain situations (e.g. driving a car or being in a crowded place) may become associated with having a panic attack. these panic attacks are not triggered by situations in which the person is the focus of others' attention (as in social phobia). the diagnosis requires four such attacks within a four week period, or one or more attacks followed by at least a month of persistent fear of having another attack. the panic attacks must be characterised by at least four of the following symptoms: dyspnoea or smothering sensations; dizziness, unsteady feelings or faintness; palpitations or tachycardia; trembling or shaking; sweating; choking; nausea or abdominal distress; depersonalisation or derealisation; paraesthesiae; flushes (hot flashes) or chills; chest pain or discomfort; fear of dying; fear of going crazy or of doing something uncontrolled. note. attacks involving four or more symptoms are panic attacks; attacks involving fewer than four are limited symptom attacks. at least some of the panic attack symptoms must develop suddenly and increase in intensity within ten minutes of the beginning of the first symptom noticed in the attack. the panic attack must not be attributable to some known organic factor, e.g. amphetamine or caffeine, intoxication, hyperthyroidism. the efficacy of alprazolam in conditions where the above criteria are not met has not been established. the risk versus benefits of alprazolam use in milder disorders, which do not meet the above criteria, has not been evaluated. although current evidence supports the long-term clinical effectiveness of alprazolam in panic disorder, the continuing use of alprazolam needs to be weighed against the difficulties that can occur with dependence and discontinuation. the results of a long-term study in patients taking alprazolam (ie. beyond three months) suggest that many patients continue to benefit from alprazolam therapy and that alprazolam efficacy is maintained for up to eight months. the physician should periodically reassess the usefulness of the drug for each patient. a comparative study of alprazolam and placebo in the treatment of panic attacks in patients with panic disorder involved 543 patients over an eight week period. alprazolam was significantly more effective than placebo in reducing the total number of panic attacks (p < 0.0001); at week 4, 46.8% of alprazolam patients had achieved zero total panic attacks when compared to 27.1% of placebo patients. panic disorders are often severe, chronic illnesses that cause a high level of work and social disability, increased substance abuse and potentially increased morbidity and mortality. psychological and social factors are important in the pathogenesis of panic attacks, either acting alone or in combination with biological factors. prolonged pharmacological therapy may be used as an adjunct to psychosocial therapy in the treatment of patients with panic disorders.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - alprazolam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; povidone; docusate sodium; colloidal anhydrous silica; indigo carmine aluminium lake; sodium starch glycollate; maize starch; erythrosine aluminium lake; lactose monohydrate; sodium benzoate - for short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. alprazolam is not recommended as primary therapy in patients with depression. for the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. indications as at 17 december 2001 : anxiety. short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. panic disorder. the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. the diagnostic criteria for panic disorder in dsm-iii-r are as follows: the panic attacks (discrete periods of intense fear or discomfort), at least initially, are unexpected. later in the course of this disturbance, certain situations (e.g. driving a car or being in a crowded place) may become associated with having a panic attack. these panic attacks are not triggered by situations in which the person is the focus of others' attention (as in social phobia). the diagnosis requires four such attacks within a four week period, or one or more attacks followed by at least a month of persistent fear of having another attack. the panic attacks must be characterised by at least four of the following symptoms: dyspnoea or smothering sensations; dizziness, unsteady feelings or faintness; palpitations or tachycardia; trembling or shaking; sweating; choking; nausea or abdominal distress; depersonalisation or derealisation; paraesthesiae; flushes (hot flashes) or chills; chest pain or discomfort; fear of dying; fear of going crazy or of doing something uncontrolled. note. attacks involving four or more symptoms are panic attacks; attacks involving fewer than four are limited symptom attacks. at least some of the panic attack symptoms must develop suddenly and increase in intensity within ten minutes of the beginning of the first symptom noticed in the attack. the panic attack must not be attributable to some known organic factor, e.g. amphetamine or caffeine, intoxication, hyperthyroidism. the efficacy of alprazolam in conditions where the above criteria are not met has not been established. the risk versus benefits of alprazolam use in milder disorders, which do not meet the above criteria, has not been evaluated. although current evidence supports the long-term clinical effectiveness of alprazolam in panic disorder, the continuing use of alprazolam needs to be weighed against the difficulties that can occur with dependence and discontinuation. the results of a long-term study in patients taking alprazolam (ie. beyond three months) suggest that many patients continue to benefit from alprazolam therapy and that alprazolam efficacy is maintained for up to eight months. the physician should periodically reassess the usefulness of the drug for each patient. a comparative study of alprazolam and placebo in the treatment of panic attacks in patients with panic disorder involved 543 patients over an eight week period. alprazolam was significantly more effective than placebo in reducing the total number of panic attacks (p < 0.0001); at week 4, 46.8% of alprazolam patients had achieved zero total panic attacks when compared to 27.1% of placebo patients. panic disorders are often severe, chronic illnesses that cause a high level of work and social disability, increased substance abuse and potentially increased morbidity and mortality. psychological and social factors are important in the pathogenesis of panic attacks, either acting alone or in combination with biological factors. prolonged pharmacological therapy may be used as an adjunct to psychosocial therapy in the treatment of patients with panic disorders.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - alprazolam, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; sodium starch glycollate; docusate sodium; maize starch; lactose monohydrate; sodium benzoate; povidone - for short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. alprazolam is not recommended as primary therapy in patients with depression. for the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.indications as at 17 december 2001 : anxiety. short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. panic disorder. the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. the diagnostic criteria for panic disorder in dsm-iii-r are as follows: the panic attacks (discrete periods of intense fear or discomfort), at least initially, are unexpected. later in the course of this disturbance, certain situations (e.g. driving a car or being in a crowded place) may become associated with having a panic attack. these panic attacks are not triggered by situations in which the person is the focus of others' attention (as in social phobia). the diagnosis requires four such attacks within a four week period, or one or more attacks followed by at least a month of persistent fear of having another attack. the panic attacks must be characterised by at least four of the following symptoms: dyspnoea or smothering sensations; dizziness, unsteady feelings or faintness; palpitations or tachycardia; trembling or shaking; sweating; choking; nausea or abdominal distress; depersonalisation or derealisation; paraesthesiae; flushes (hot flashes) or chills; chest pain or discomfort; fear of dying; fear of going crazy or of doing something uncontrolled. note. attacks involving four or more symptoms are panic attacks; attacks involving fewer than four are limited symptom attacks. at least some of the panic attack symptoms must develop suddenly and increase in intensity within ten minutes of the beginning of the first symptom noticed in the attack. the panic attack must not be attributable to some known organic factor, e.g. amphetamine or caffeine, intoxication, hyperthyroidism. the efficacy of alprazolam in conditions where the above criteria are not met has not been established. the risk versus benefits of alprazolam use in milder disorders, which do not meet the above criteria, has not been evaluated. although current evidence supports the long-term clinical effectiveness of alprazolam in panic disorder, the continuing use of alprazolam needs to be weighed against the difficulties that can occur with dependence and discontinuation. the results of a long-term study in patients taking alprazolam (ie. beyond three months) suggest that many patients continue to benefit from alprazolam therapy and that alprazolam efficacy is maintained for up to eight months. the physician should periodically reassess the usefulness of the drug for each patient. a comparative study of alprazolam and placebo in the treatment of panic attacks in patients with panic disorder involved 543 patients over an eight week period. alprazolam was significantly more effective than placebo in reducing the total number of panic attacks (p < 0.0001); at week 4, 46.8% of alprazolam patients had achieved zero total panic attacks when compared to 27.1% of placebo patients. panic disorders are often severe, chronic illnesses that cause a high level of work and social disability, increased substance abuse and potentially increased morbidity and mortality. psychological and social factors are important in the pathogenesis of panic attacks, either acting alone or in combination with biological factors. prolonged pharmacological therapy may be used as an adjunct to psychosocial therapy in the treatment of patients with panic disorders.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - tenofovir alafenamide, quantity: 10 mg; darunavir, quantity: 800 mg; cobicistat, quantity: 150 mg; emtricitabine, quantity: 200 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; silicon dioxide; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - symtuza is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). genotypic testing should guide the use of symtuza (see section 4.2 dose and method of administration, section 4.4 special warnings and precautions for use and section 5.1 pharmacodynamic properties).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - agomelatine, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; stearic acid; colloidal anhydrous silica; sodium starch glycollate type a; maize starch; lactose monohydrate; propylene glycol; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; indigo carmine aluminium lake; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; glycerol - treatment in adults of: - of major depression (mdd) including prevention of relapse - generalised anxiety disorder (gad)

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - citalopram hydrobromide, quantity: 49.96 mg (equivalent: citalopram, qty 40 mg) - tablet, film coated - excipient ingredients: copovidone; microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; purified water; maize starch; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - citalopram hydrobromide, quantity: 24.98 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; copovidone; microcrystalline cellulose; purified water; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for treatment of major depression

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: purified water; croscarmellose sodium; lactose monohydrate; maize starch; copovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - agomelatine, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; stearic acid; colloidal anhydrous silica; sodium starch glycollate type a; maize starch; lactose monohydrate; propylene glycol; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; indigo carmine aluminium lake; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; glycerol - treatment in adults of: - of major depression (mdd) including prevention of relapse - generalised anxiety disorder (gad)

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fosinopril sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: zinc stearate; crospovidone; lactose - hypertension - treatment of mild to moderate hypertension. fosinopril is effective alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of fosinopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of fosinopril in severe or renovascular hypertension. heart failure - management of heart failure when added to conventional therapy, including diuretics.